Fusion Antibodies Plc (GB:FAB)
LSE:FAB
FAB Stock Chart & Stats
14.50 p
0.15 p(1.82%)
At close: 4:00 PM EST
14.50 p
0.15 p(1.82%)
Day’s Range― - ―
52-Week Range5.60 p - 21.00 p
Previous CloseN/A
Volume21.95K
Average Volume (3M)1.16M
Market Cap
£15.94M
Enterprise Value16.36M
Total Cash (Recent Filing)£252.00K
Total Debt (Recent Filing)£671.00K
Price to Earnings (P/E)―
Beta-0.18
Next Earnings
Sep 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding125,021,880
10 Day Avg. Volume2,164,859
30 Day Avg. Volume1,162,225
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)8.81
Price to Sales (P/S)3.00
P/FCF Ratio-4.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Outsourced CRO Business ModelFusion operates a fee-for-service CRO model supplying antibody discovery and engineering to biotech, pharma and diagnostics. This model benefits from structural outsourcing trends, providing recurring project revenue, client diversification by therapeutic area, and relatively predictable demand for lab services over months.
Low Financial LeverageMinimal leverage (debt/equity ~0.03) and a ~50% equity ratio give the company financial flexibility to withstand volatile cash flows common in small biotech services firms. Low debt reduces fixed interest burdens and preserves capacity to raise non-debt financing for R&D or working capital needs over the medium term.
Improving Top-line And Gross MarginRevenue growth and a rising gross margin (21.9%) indicate improving core unit economics in service delivery. If sustained, better gross margins provide a path to absorb overhead and move toward operating leverage, making eventual profitability more attainable as sales scale over the next several quarters.
Bears Say
Severe UnprofitabilityExtremely negative EBIT and net margins show the business currently loses large amounts on operations, meaning revenue growth alone may not be sufficient. Persistent deep losses erode capital, limit reinvestment, and require corrective cost or pricing changes to achieve sustainable profitability over the 2–6 month horizon.
Weak Operating Cash FlowNegative operating cash flow indicates the company is not converting reported revenue into cash, forcing reliance on financing or equity to fund operations. A negative OCF/net income ratio signals cash burn beyond accounting losses, constraining capacity to fund projects or scale without external capital in the medium term.
Eroded Shareholder Value (ROE)A dramatically negative ROE implies shareholder equity is being consumed rather than generating returns. This undermines investor confidence, makes equity financing dilutive or costly, and signals structural profitability shortfalls that could force strategic changes or capital raises detrimental to existing holders.
Fusion Antibodies Plc News
FAB FAQ
What was Fusion Antibodies Plc’s price range in the past 12 months?
Fusion Antibodies Plc lowest share price was 5.60 p and its highest was 21.00 p in the past 12 months.
What is Fusion Antibodies Plc’s market cap?
Fusion Antibodies Plc’s market cap is £15.94M.
When is Fusion Antibodies Plc’s upcoming earnings report date?
Fusion Antibodies Plc’s upcoming earnings report date is Sep 03, 2026 which is in 158 days.
How were Fusion Antibodies Plc’s earnings last quarter?
Fusion Antibodies Plc released its earnings results on Nov 24, 2025. The company reported -0.005 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.005 p.
Is Fusion Antibodies Plc overvalued?
According to Wall Street analysts Fusion Antibodies Plc’s price is currently Overvalued.
Does Fusion Antibodies Plc pay dividends?
Fusion Antibodies Plc does not currently pay dividends.
What is Fusion Antibodies Plc’s EPS estimate?
Fusion Antibodies Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Fusion Antibodies Plc have?
Fusion Antibodies Plc has 125,021,880 shares outstanding.
What happened to Fusion Antibodies Plc’s price movement after its last earnings report?
Fusion Antibodies Plc reported an EPS of -0.005 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.083%.
Which hedge fund is a major shareholder of Fusion Antibodies Plc?
Currently, no hedge funds are holding shares in GB:FAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Fusion Antibodies Plc
Fusion Antibodies Plc (FAB) is a biotechnology company specializing in the development and production of fully human monoclonal antibodies. The company operates primarily in the life sciences sector, providing a range of services including antibody discovery, engineering, and development. Fusion Antibodies focuses on offering tailored solutions to pharmaceutical and biotechnology companies, helping them accelerate their drug discovery processes and enhance the efficacy of therapeutic antibodies.
Technical Analysis
Avacta Group plc
―
Bioventix
―
Scancell Holdings
―
Genflow Biosciences Plc
―
Aptamer Group Plc
―
Options Prices
Currently, No data available
---